Abstract:OBJECTIVETo investigate the expression level of Shp-2 tyrosine phosphatase in chronic myeloid leukemia (CML) and its relationship with the unlimited growth and apoptosis resistance of p210 bcr/abl-induced malignant cells.METHODSIn this study, p210 bcr/abl positive leukemia cell specimens were obtained from 25 CML cases, meanwhile, bone marrow and peripheral blood cell samples from 8 non-tumor individuals and 10 normal individuals were used as p210 bcr/abl negative controls. K562 and KU812 leukemia cells were used as p210 bcr/abl positive controls, and KG-1 leukemia cell line was used as Shp-2 positive control. Specimens of peripheral blood and bone marrow of 25 adult patients of chronic myelocytic leukemia, 15 males and 10 females, aged 28-64, were collected. Specimens of bone marrow of 8 basically healthy adult volunteers and specimens of peripheral blood of 10 healthy adult volunteers were used as controls. The total cell protein was collected and the expression of Shp-2 was examined by Western blotting. Human leukemia cells of the line K562 were cultured. Shp-2 specific sense and antisense oligonucleotides were added into the culture fluid respectively. The cell apoptosis was detected by flow cytometry (FCM). STI571, specific inhibitor of p210 bcr/abl was added into the cultured fluid of K562 cells, then Western blotting and FCM were used to detect the protein expression of Shp-2 and p210 bcr/abl, and cell apoptosis.RESULTSPhosphorylated Shp-2 (pShp)-2 protein was overexpressed in 92% (23/25) of the CML cells, but lowly expressed or not expressed in the normal hematopoietic cells. The mean pShp-2 protein/beta-actin ratio of the primary CML leukemia cells was 0.91 +/- 0.62, significantly higher than those of the normal bone marrow cells and peripheral blood hematopoietic cells (0.16 +/- 0.09 and 0.03 +/- 0.05 respectively, both P < 0.01). The apoptotic rates of the CML cells treated by Shp-2 specific antisense oligonucleotide of the concentrations of 1 micromol/L and 4 micromol/L respectively for 72 h was 7.98% and 20.29% respectively, both significantly higher than that of the control group (4.06%, P < 0.01). The number of clone of CML cells treated by 0.25 micromol/L and 1.0 micromol/L Shp-2 specific antisense oligonucleotide for 7 days were 67% (37/60) and 11.9% (5/42) that of the control group. Twenty-four and 48 hours after the stimulation of STI571 the expression level of Shp-2 protein in the CML cells decreased time-dependently and the CML cell apoptotic rates were 31.15% and 38.69% respectively, both lower than that of the control group (33.6%). The number of clone of CML cells effected by 0.25 micromol/L and 1.0 micromol/L Shp-2 specific antisense oligonucleotide for 7 days was 67% (37/60) and 11.9% (5/42) that of the control group. Twenty-four and 48 hours after the stimulation of STI571 the expression level of Shp-2 protein in the CML cells decreased time-dependently and the CML cell apoptotic rates were 31.15% and 38.69% respectively, both lower than that of the control group (33.6%).CONCLUSION(1) The pShp-2 protein is overexpressed in CML cells, which is associated with the unlimited growth and apoptosis resistance of malignant cells. (2) Shp-2 is upregulated by p210 bcr/abl oncoprotein in CML.

Epigenetic Inactivation of PLCD 1 in Chronic Myeloid Leukemia

Phospholipase C Delta 1 is a Novel 3p22.3 Tumor Suppressor Involved in Cytoskeleton Organization, with Its Epigenetic Silencing Correlated with High-Stage Gastric Cancer

Expression and Clinical Significance of Phospholipase D1 in De Novo Acute Myeloid Leukemia

PLCD1 is a Functional Tumor Suppressor Inducing G(2)/M Arrest and Frequently Methylated in Breast Cancer.

Expression and Functions of the STAT3-SCLIP Pathway in Chronic Myeloid Leukemia Cells.

Phospholipase C Delta 1 Inhibits WNT/β‐catenin and EGFR-FAK-ERK Signaling and is Disrupted by Promoter CpG Methylation in Renal Cell Carcinoma

The Phosphoinositide Hydrolase Phospholipase C Delta1 Inhibits Epithelial-Mesenchymal Transition And Is Silenced In Colorectal Cancer

Epigenetic identification of CHD5 as a critical 1p36.3 tumor suppressor frequently inactivated by promoter methylation in multiple carcinomas

The role of CSE1L silencing in the regulation of proliferation and apoptosis via the AMPK/mTOR signaling pathway in chronic myeloid leukemia

Detection of FLT3/ITD, JAK2(V617F) and NPM1 gene mutations in chronic myelomonocytic leukemia

[Overexpression of Shp-2 is Associated with the Unlimited Growth and Apoptosis Resistance of P210 Bcr-Abl-mediated Chronic Myeloid Leukemia].

Eradication of Chronic Myelogenous Leukemia by Inactivation of the Polycomb Group Protein Ezh2

PLK1 Stabilizes a MYC-dependent Kinase Network in Aggressive B Cell Lymphomas

Epigenetic Silencing of the 3p22 Tumor Suppressor DLEC1 by Promoter CpG Methylation in Non-Hodgkin and Hodgkin Lymphomas

Scd1 Plays a Tumor-Suppressive Role in Survival of Leukemia Stem Cells and the Development of Chronic Myeloid Leukemia

Repression of CDKN2C Caused by PML/RARα Binding Promotes the Proliferation and Differentiation Block in Acute Promyelocytic Leukemia

[Down-Regulation of Transcription Factor PU.1 Via Abnormal Epigenetic Modification in Chronic Myeloid Leukemia].

Promoter Hypermethylation of PTPL1, PTPN6, DAPK, P16 and 5-Azacitidine Inhibits Growth in DLBCL.

CIP2A is Overexpressed and Involved in the Pathogenesis of Chronic Myelocytic Leukemia by Interacting with Breakpoint Cluster Region-Abelson Leukemia Virus

Down-regulation of hematopoiesis master regulator PU.1 via aberrant methylation in chronic myeloid leukemia

Research on the epigenetic regulation mechanism of the PTPN6 gene in advanced chronic myeloid leukaemia